To raise awareness and understanding of neuroendocrine tumours (NETs), both within the medical profession and the wider Australian public, and provide support to our NET community.
To assist and support patients and carers; lobby for new, appropriate treatments and investigations; raise awareness and knowledge of NETs within the medical community and general public and encourage and support NET Research.
Our vision continues to be the
champions of earlier diagnosis
and a cure for neuroendocrine
cancer.
Cultivate growth and compassion through patient care and support.
Ignite confidence to create positive change.
Demonstrate genuine concern and empathy for the well-being of others.
Take responsibility for our actions with integrity and transparency.
We will achieve the strategic priorities through activities that fall within our pillars.
These priorities will set the goals we are aiming to achieve in the next 3 years (2023 – 2025).
In 2024 a Senate Recommendation was released in response to the inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer’. This inquiry sought to address the significant barriers faced by patients in obtaining timely and effective cancer care.
In 2024 a Senate Recommendation was released in response to the inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer’. This inquiry sought to address the significant barriers faced by patients in obtaining timely and effective cancer care.
In 2024 a Senate Recommendation was released in response to the inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer’. This inquiry sought to address the significant barriers faced by patients in obtaining timely and effective cancer care.
In 2024 a Senate Recommendation was released in response to the inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer’. This inquiry sought to address the significant barriers faced by patients in obtaining timely and effective cancer care.
In 2024 a Senate Recommendation was released in response to the inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer’. This inquiry sought to address the significant barriers faced by patients in obtaining timely and effective cancer care.
In 2024 a Senate Recommendation was released in response to the inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer’. This inquiry sought to address the significant barriers faced by patients in obtaining timely and effective cancer care.
NECA’s National Action Plan, plans to establish and consolidate across 8 key areas over the next five-year period. Key action points 2 & 8 relate specifically to this section.
NECA’s National Action Plan, plans to establish and consolidate across 8 key areas over the next five-year period. Key action points 6 & 8 relate specifically to this section.
NECA’s National Action Plan, plans to establish and consolidate across 8 key areas over the next five-year period. Key action points 4 & 5 relate specifically to this section.
NECA’s National Action Plan, plans to establish and consolidate across 8 key areas over the next five-year period. Key action point 3 relates specifically to this section.
NECA’s National Action Plan, plans to establish and consolidate across 8 key areas over the next five-year period. Key action points 1 & 2 relate specifically to this section.
